There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Merck has also decided to end the favezelimab clinical development program
ALS patients experience neuroinflammation and rapid neurodegeneration
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Subscribe To Our Newsletter & Stay Updated
